Evidence map›Paper›PMID 25820765›Full record

ArticleAnnals of internal medicine2015

A cure for the high cost of hepatitis C virus treatment.

Ohad Etzion, Marc G Ghany

Abstract readEditorialComment
In one paragraph

Article in Annals of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Marmosets as models of infectious diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  3. Article
  4. Observational
  5. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2016
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ohad Etzion
Marc G Ghany

Funding

Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis CZIADK075009 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GHANY, MARC · 2009 to 2025
$7.2M
Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis CZ01DK075009 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GHANY, MARC · 2008 to 2008
$378k
Intramural NIH HHS Z01 DK075009
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cost-Benefit AnalysisAntiviral AgentsHepatitis C, ChronicHumansUridine MonophosphateAntiviral AgentsUridine Monophosphate

Identifiers

PMID25820765
PMCPMC7460276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.